TITLE

Government-Owned Inventions; Availability for Licensing

AUTHOR(S)
Rodriguez, Richard U.
PUB. DATE
May 2012
SOURCE
Federal Register (National Archives & Records Service, Office of;5/15/2012, Vol. 77 Issue 94, p28608
SOURCE TYPE
Government Documents
DOC. TYPE
Article
ABSTRACT
The article reports on a notice issued by the U.S. National Institutes of Health for availability of the U.S. government inventions for licensing. This notice has been issued for achieving expeditious commercialization of federally funded research and development. These inventions are related to ribonucleic acid for human immunodeficiency virus infection treatment, isolation of hybridomas producing monoclonal antibodies and the use of biomarker for treatment of colon, lung and ovarian cancers.
ACCESSION #
76111851

 

Related Articles

  • (MINORITIES) Applicants Vie for $6M in Disparities Funding.  // Children & Youth Funding Report;4/8/2011, p8 

    The article presents information on funding opportunity offered by the U.S. National Institutes of Health under the Resource-Related Minority Health and Health Disparities Research program. Information on the funding opportunity number, eligibility for the funding, fund amount and deadline is...

  • Center for Scientific Review; Notice of Closed Meetings. Spaeth, Jennifer S. // Federal Register (National Archives & Records Service, Office of;2/24/2012, Vol. 77 Issue 37, p11138 

    The article offers information on several conference organized by the U.S. National Institutes of Health to review and evaluate grant applications to be held in Bethesda, Maryland from March 13-29, 2012. applications at Bethesda, Maryland from March 13-14, 2012 ,

  • Center for Scientific Review; Notice of Closed Meetings. Spaeth, Jennifer S. // Federal Register (National Archives & Records Service, Office of;2/24/2012, Vol. 77 Issue 37, p11139 

    The article offers information on several conference organized by the U.S. National Institutes of Health to review and evaluate grant applications to be held in Bethesda, Maryland from March 12-22, 2012.

  • Cancer Immunotherapy. Bayer, Virginia; Amaya, Beau; Baniewicz, Diane; Callahan, Colleen; Marsh, Lisa; McCoy, Asia S. // Clinical Journal of Oncology Nursing;Apr2017, Vol. 21 Issue 2, p15 

    BACKGROUND: Significant research progress has been made in immunotherapies since the mid-1990s, and this rapid evolution necessitates evidence-based education on immunotherapies, their pathophysiology, and their toxicities to provide safe, effective care. OBJECTIVES: The aim of this article is...

  • Government-Owned Inventions; Availability for Licensing. Rodriguez, Richard U. // Federal Register (National Archives & Records Service, Office of;10/23/2012, Vol. 77 Issue 205, p64810 

    The article offers information on a notice issued by the U.S. National Institutes of Health. The notice focuses on the government-owned inventions which are available for licensing for achieving effective commercialization of results of federally-funded research and development. The notice...

  • Small probe takes OCT deep into the body. Schneider, Ilene // Laser Focus World;Jul2003, Vol. 39 Issue 7, p32 

    Reports on the significance of a National Institutes of Health grant to develop a microscopic probe according to a research team at the University of California-Irvine. Usability of the microscope probe to detect and treat precancerous and malignant tumors in humans; Development of techniques...

  • LEGISLATION.  // BioScience;Jan1967, Vol. 17 Issue 1, p45 

    The article offers news briefs related to various laws concerning science in the U.S. The Educational, Scientific and Cultural Materials Importation Act of 1966 has been passed by the U.S. Congress. The Congress has appropriated $1,412.9 million for the National Institutes of Health (NIH). A...

  • ADVANCED. Immunotherapy method effective against various cancers.  // Dermatology Times;Jun2014, Vol. 35 Issue 6, p10 

    The article discusses a study led by Doctor Steven A. Rosenberg of the National Cancer Institute's (NCI) Center for Cancer Research on whether tumor-infiltrating lymphocytes (TILs) from patients with metastatic gastrointestinal cancers can recognize patient-specific mutations. Topics discussed...

  • Prospective Grant of Exclusive License: The Development of Anti- CD22 Chimeric Antigen Receptors (CARs) for the Treatment of B Cell Malignancies. Rodriguez, Richard U. // Federal Register (National Archives & Records Service, Office of;10/15/2012, Vol. 77 Issue 199, p62520 

    The article focuses on a notice issued by the U.S. National Institutes of Health (NIH) regarding an exclusive license granted to Neomune Inc. License on patent applications entitled "Anti-CD22 Chimeric Antigen Receptors (CARs)" and "Mutated Anti-CD22 Antibodies with Increased Affinity to CD22...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics